Malnutrition in Cirrhosis: Contribution and Consequences of Sarcopenia on Metabolic and Clinical Responses

Clinics in Liver Disease

Volumn 16, Issue 1, 2012, Pages 95-131

  Periyalwar, Pranav ^a,b   Dasarathy, Srinivasan ^b  

^a METROHEALTH MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cirrhosis; Malnutrition; Metabolism; Sarcopenia

Indexed keywords

SOMATOMEDIN C; TRACE ELEMENT;

ADIPOSE TISSUE; AEROBIC EXERCISE; AGING; CELL FUNCTION; DIET SUPPLEMENTATION; DISEASE SEVERITY; HUMAN; LEAN BODY WEIGHT; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; MALNUTRITION; MUSCLE ATROPHY; MUSCLE MASS; NUTRITIONAL ASSESSMENT; PATHOGENESIS; PORTOSYSTEMIC ANASTOMOSIS; PROTEIN METABOLISM; QUALITY OF LIFE; RESISTANCE TRAINING; REVIEW; SATELLITE CELL; SKELETAL MUSCLE; SURVIVAL;

DIETARY PROTEINS; HUMANS; LIVER CIRRHOSIS; MALNUTRITION; MUSCLE, SKELETAL; SARCOPENIA;

EID: 84856605540     PISSN: 10893261     EISSN: 15578224     Source Type: Journal    
DOI: 10.1016/j.cld.2011.12.009     Document Type: Review

References (192)

1. Tessari P. Protein metabolism in liver cirrhosis: from albumin to muscle myofibrils. Curr Opin Clin Nutr Metab Care 2003, 6(1):79-85.
2. Bianchi G., Marzocchi R., Agostini F., et al. Update on nutritional supplementation with branched-chain amino acids. Curr Opin Clin Nutr Metab Care 2005, 8(1):83-87.
3. Bilbao I., Armadans L., Lazaro J.L., et al. Predictive factors for early mortality following liver transplantation. Clin Transplant 2003, 17(5):401-411.
4. Alvares-da-Silva M.R., Reverbel da S.T. Comparison between handgrip strength, subjective global assessment, and prognostic nutritional index in assessing malnutrition and predicting clinical outcome in cirrhotic outpatients. Nutrition 2005, 21(2):113-117.
5. Selberg O., Bottcher J., Tusch G., et al. Identification of high- and low-risk patients before liver transplantation: a prospective cohort study of nutritional and metabolic parameters in 150 patients. Hepatology 1997, 25(3):652-657.
6. Kalaitzakis E., Simren M., Olsson R., et al. Gastrointestinal symptoms in patients with liver cirrhosis: associations with nutritional status and health-related quality of life. Scand J Gastroenterol 2006, 41(12):1464-1472.
7. Kalaitzakis E., Olsson R., Henfridsson P., et al. Malnutrition and diabetes mellitus are related to hepatic encephalopathy in patients with liver cirrhosis. Liver Int 2007, 27(9):1194-1201.
8. Huisman E.J., Trip E.J., Siersema P.D., et al. Protein energy malnutrition predicts complications in liver cirrhosis. Eur J Gastroenterol Hepatol 2011, 23(11):982-989.
9. Merli M., Lucidi C., Giannelli V., et al. Cirrhotic patients are at risk for health care-associated bacterial infections. Clin Gastroenterol Hepatol 2010, 8(11):979-985.
10. Merli M., Giusto M., Gentili F., et al. Nutritional status: its influence on the outcome of patients undergoing liver transplantation. Liver Int 2010, 30(2):208-214.
11. O'Brien A., Williams R. Nutrition in end-stage liver disease: principles and practice. Gastroenterology 2008, 134(6):1729-1740.
12. Kerwin A.J., Nussbaum M.S. Adjuvant nutrition management of patients with liver failure, including transplant. Surg Clin North Am 2011, 91(3):565-578.
13. Ferreira L.G., Anastacio L.R., Correia M.I. The impact of nutrition on cirrhotic patients awaiting liver transplantation. Curr Opin Clin Nutr Metab Care 2010, 13(5):554-561.
14. Argiles J.M., Anker S.D., Evans W.J., et al. Consensus on cachexia definitions. JAm Med Dir Assoc 2010, 11(4):229-230.
15. Evans W.J., Morley J.E., Argiles J., et al. Cachexia: a new definition. Clin Nutr 2008, 27(6):793-799.
16. Montano-Loza A.J., Meza-Junco J., Prado C.M., et al. Sarcopenia is associated with mortality in patients with cirrhosis. Clin Gastroenterol Hepatol 2011, [Epub ahead of print].
17. Englesbe M.J., Patel S.P., He K., et al. Sarcopenia and mortality after liver transplantation. JAm Coll Surg 2010, 211(2):271-278.
18. Peng S., Plank L.D., McCall J.L., et al. Body composition, muscle function, and energy expenditure in patients with liver cirrhosis: a comprehensive study. Am J Clin Nutr 2007, 85(5):1257-1266.
19. Alberino F., Gatta A., Amodio P., et al. Nutrition and survival in patients with liver cirrhosis. Nutrition 2001, 17(6):445-450.
20. Campillo B., Richardet J.P., Bories P.N. Enteral nutrition in severely malnourished and anorectic cirrhotic patients in clinical practice. Gastroenterol Clin Biol 2005, 29(6-7):645-651.
21. Plauth M., Schutz E.T. Cachexia in liver cirrhosis. Int J Cardiol 2002, 85(1):83-87.
22. Tsien C.D., McCullough A.J., Dasarathy S. Late evening snack - exploiting a period of anabolic opportunity in cirrhosis. JGastroenterol Hepatol 2011, [Epub ahead of print].
23. Nutritional status in cirrhosis. Italian multicentre cooperative project on nutrition in liver cirrhosis. JHepatol 1994, 21(3):317-325.
24. Lata J., Husova L., Jurankova J., et al. Factors participating in the development and mortality of variceal bleeding in portal hypertension-possible effects of the kidney damage and malnutrition. Hepatogastroenterology 2006, 53(69):420-425.
25. Gunsar F., Raimondo M.L., Jones S., et al. Nutritional status and prognosis in cirrhotic patients. Aliment Pharmacol Ther 2006, 24(4):563-572.
26. Marchesini G., Marzocchi R., Noia M., et al. Branched-chain amino acid supplementation in patients with liver diseases. JNutr 2005, 135(Suppl 6):1596S-1601S.
27. Kato M., Miwa Y., Tajika M., et al. Preferential use of branched-chain amino acids as an energy substrate in patients with liver cirrhosis. Intern Med 1998, 37(5):429-434.
28. Tsiaousi E.T., Hatzitolios A.I., Trygonis S.K., et al. Malnutrition in end stage liver disease: recommendations and nutritional support. JGastroenterol Hepatol 2008, 23(4):527-533.
29. Charlton M. Branched-chain amino acid enriched supplements as therapy for liver disease. JNutr 2006, 136(Suppl 1):295S-298S.
30. Conchillo M., de Knegt R.J., Payeras M., et al. Insulin-like growth factor I (IGF-I) replacement therapy increases albumin concentration in liver cirrhosis: results of a pilot randomized controlled clinical trial. JHepatol 2005, 43(4):630-636.
31. Zaratiegui M., Castilla-Cortazar I., Garcia M., et al. IGF1 gene transfer into skeletal muscle using recombinant adeno-associated virus in a rat model of liver cirrhosis. JPhysiol Biochem 2002, 58(3):169-176.
32. Bucuvalas J.C., Horn J.A., Chernausek S.D. Resistance to growth hormone in children with chronic liver disease. Pediatr Transplant 1997, 1(1):73-79.
33. Biolo G., Antonione R., Barazzoni R., et al. Mechanisms of altered protein turnover in chronic diseases: a review of human kinetic studies. Curr Opin Clin Nutr Metab Care 2003, 6(1):55-63.
34. Glass D., Roubenoff R. Recent advances in the biology and therapy of muscle wasting. Ann N Y Acad Sci 2010, 1211:25-36.
35. Ruegg M.A., Glass D.J. Molecular mechanisms and treatment options for muscle wasting diseases. Annu Rev Pharmacol Toxicol 2011, 51:373-395.
36. Dasarathy S., McCullough A.J., Muc S., et al. Sarcopenia associated with portosystemic shunting is reversed by follistatin. JHepatol 2011, 54(5):915-921.
37. Gayan-Ramirez G., van de Casteele M., Rollier H., et al. Biliary cirrhosis induces type IIx/b fiber atrophy in rat diaphragm and skeletal muscle, and decreases IGF-I mRNA in the liver but not in muscle. JHepatol 1998, 29(2):241-249.
38. Dasarathy S., Dodig M., Muc S.M., et al. Skeletal muscle atrophy is associated with an increased expression of myostatin and impaired satellite cell function in the portacaval anastomosis rat. Am J Physiol Gastrointest Liver Physiol 2004, 287(6):G1124-G1130.
39. Dasarathy S., Muc S., Hisamuddin K., et al. Altered expression of genes regulating skeletal muscle mass in the portacaval anastomosis rat. Am J Physiol Gastrointest Liver Physiol 2007, 292(4):G1105-G1113.
40. Dasarathy S., Mullen K.D., Dodig M., et al. Inhibition of aromatase improves nutritional status following portacaval anastomosis in male rats. JHepatol 2006, 45(2):214-220.
41. Canturk N.Z., Canturk Z., Ozden M., et al. Protective effect of IGF-1 on experimental liver cirrhosis-induced common bile duct ligation. Hepatogastroenterology 2003, 50(54):2061-2066.
42. Holecek M., Kandar R., Sispera L., et al. Acute hyperammonemia activates branched-chain amino acid catabolism and decreases their extracellular concentrations: different sensitivity of red and white muscle. Amino Acids 2011, 40(2):575-584.
43. Sriram S., Subramanian S., Sathiakumar D., et al. Modulation of reactive oxygen species in skeletal muscle by myostatin is mediated through NF-kappaB. Aging Cell 2011, 10(6):931-948.
44. Chinn K.S. Prediction of muscle and remaining tissue protein in man. JAppl Physiol 1967, 23(5):713-715.
45. Krzywicki H.J., Chinn K.S. Body composition of a military population, Fort Carson, 1963. I. Body density, fat, and potassium 40. Am J Clin Nutr 1967, 20(7):708-715.
46. Krzywicki H.J., Chinn K.S. Human body density and fat of an adult male population as measured by water displacement. Am J Clin Nutr 1967, 20(4):305-310.
47. Krzywicki H.J., Chinn K.S. Body composition of a military population, Fort Carson, 1963. I. Body density, fat and potassium 40. Lab Rep 296. Rep US Army Med Res Nutr Lab Denver 1966, 22:1-17.
48. DiCecco S.R., Wieners E.J., Wiesner R.H., et al. Assessment of nutritional status of patients with end-stage liver disease undergoing liver transplantation. Mayo Clin Proc 1989, 64(1):95-102.
49. Hasse J., Strong S., Gorman M.A., et al. Subjective global assessment: alternative nutrition-assessment technique for liver-transplant candidates. Nutrition 1993, 9(4):339-343.
50. Hasse J.M. Nutritional implications of liver transplantation. Henry Ford Hosp MedJ 1990, 38(4):235-240.
51. O'Keefe S.J., El-Zayadi A.R., Carraher T.E., et al. Malnutrition and immuno-incompetence in patients with liver disease. Lancet 1980, 2(8195 pt 1):615-617.
52. Sobhonslidsuk A., Roongpisuthipong C., Nantiruj K., et al. Impact of liver cirrhosis on nutritional and immunological status. JMed Assoc Thai 2001, 84(7):982-988.
53. Francoz C., Prie D., Abdelrazek W., et al. Inaccuracies of creatinine and creatinine-based equations in candidates for liver transplantation with low creatinine: impact on the model for end-stage liver disease score. Liver Transpl 2010, 16(10):1169-1177.
54. Thuluvath P.J., Triger D.R. How valid are our reference standards of nutrition?. Nutrition 1995, 11(6):731-733.
55. Thuluvath P.J., Triger D.R. Evaluation of nutritional status by using anthropometry in adults with alcoholic and nonalcoholic liver disease. Am J Clin Nutr 1994, 60(2):269-273.
56. Pikul J., Sharpe M.D., Lowndes R., et al. Degree of preoperative malnutrition is predictive of postoperative morbidity and mortality in liver transplant recipients. Transplantation 1994, 57(3):469-472.
57. Fuller N.J., Jebb S.A., Goldberg G.R., et al. Inter-observer variability in the measurement of body composition. Eur J Clin Nutr 1991, 45(1):43-49.
58. Godoy R., Goodman E., Levins R., et al. Anthropometric variability in the USA: 1971-2002. Ann Hum Biol 2005, 32(4):469-486.
59. Akerman P.A., Jenkins R.L., Bistrian B.R. Preoperative nutrition assessment in liver transplantation. Nutrition 1993, 9(4):350-356.
60. Horber F.F., Thomi F., Casez J.P., et al. Impact of hydration status on body composition as measured by dual energy x-ray absorptiometry in normal volunteers and patients on haemodialysis. Br J Radiol 1992, 65(778):895-900.
61. Pirlich M., Schutz T., Spachos T., et al. Bioelectrical impedance analysis is a useful bedside technique to assess malnutrition in cirrhotic patients with and without ascites. Hepatology 2000, 32(6):1208-1215.
62. Madden A.M., Morgan M.Y. The potential role of dual-energy x-ray absorptiometry in the assessment of body composition in cirrhotic patients. Nutrition 1997, 13(1):40-45.
63. Morgan M.Y., Madden A.M., Jennings G., et al. Two-component models are of limited value for the assessment of body composition in patients with cirrhosis. Am J Clin Nutr 2006, 84(5):1151-1162.
64. Chinn K.S., Hannon J.P. Relationship of muscle protein to other components of the fat-free mass. Am J Physiol 1966, 211(4):993-997.
65. Morgan M.Y., Madden A.M. The assessment of body composition in patients with cirrhosis. Eur J Nucl Med 1996, 23(2):213-225.
66. Madden A.M., Morgan M.Y. Acomparison of skinfold anthropometry and bioelectrical impedance analysis for measuring percentage body fat in patients with cirrhosis. JHepatol 1994, 21(5):878-883.
67. Fuller N.J., Jebb S.A., Laskey M.A., et al. Four-component model for the assessment of body composition in humans: comparison with alternative methods, and evaluation of the density and hydration of fat-free mass. Clin Sci (Lond) 1992, 82(6):687-693.
68. Mendenhall C.L., Anderson S., Weesner R.E., et al. Protein-calorie malnutrition associated with alcoholic hepatitis. Veterans Administration Cooperative Study Group on Alcoholic Hepatitis. Am J Med 1984, 76(2):211-222.
69. Lautz H.U., Selberg O., Korber J., et al. Protein-calorie malnutrition in liver cirrhosis. Clin Investig 1992, 70(6):478-486.
70. Addolorato G., Capristo E., Greco A.V., et al. Influence of chronic alcohol abuse on body weight and energy metabolism: is excess ethanol consumption a risk factor for obesity or malnutrition?. JIntern Med 1998, 244(5):387-395.
71. Caly W.R., Strauss E., Carrilho F.J., et al. Different degrees of malnutrition and immunological alterations according to the aetiology of cirrhosis: a prospective and sequential study. Nutr J 2003, 2:10.
72. Caregaro L., Alberino F., Amodio P., et al. Malnutrition in alcoholic and virus-related cirrhosis. Am J Clin Nutr 1996, 63(4):602-609.
73. Roongpisuthipong C., Sobhonslidsuk A., Nantiruj K., et al. Nutritional assessment in various stages of liver cirrhosis. Nutrition 2001, 17(9):761-765.
74. Figueiredo F.A., De Mello P.R., Kondo M. Effect of liver cirrhosis on body composition: evidence of significant depletion even in mild disease. JGastroenterol Hepatol 2005, 20(2):209-216.
75. Lehnert M.E., Clarke D.D., Gibbons J.G., et al. Estimation of body water compartments in cirrhosis by multiple-frequency bioelectrical-impedance analysis. Nutrition 2001, 17(1):31-34.
76. de Carvalho L., Parise E.R., Samuel D. Factors associated with nutritional status in liver transplant patients who survived the first year after transplantation. JGastroenterol Hepatol 2010, 25(2):391-396.
77. Hehir D.J., Jenkins R.L., Bistrian B.R., et al. Nutrition in patients undergoing orthotopic liver transplant. JPEN J Parenter Enteral Nutr 1985, 9(6):695-700.
78. Loguercio C., Sava E., Sicolo P., et al. Nutritional status and survival of patients with liver cirrhosis: anthropometric evaluation. Minerva Gastroenterol Dietol 1996, 42(2):57-60.
79. Mills P.R., Shenkin A., Anthony R.S., et al. Assessment of nutritional status and invivo immune responses in alcoholic liver disease. Am J Clin Nutr 1983, 38(6):849-859.
80. Reisman Y., Gips C.H., Lavelle S.M. Assessment of liver cirrhosis severity in 1015 patients of the Euricterus database with Campbell-Child, Pugh-Child and with ascites and ascites-nutritional state (ANS) related classifications. Euricterus Project Management Group. Hepatogastroenterology 1997, 44(17):1376-1384.
81. Sam J., Nguyen G.C. Protein-calorie malnutrition as a prognostic indicator of mortality among patients hospitalized with cirrhosis and portal hypertension. Liver Int 2009, 29(9):1396-1402.
82. Tai M.L., Goh K.L., Mohd-Taib S.H., et al. Anthropometric, biochemical and clinical assessment of malnutrition in Malaysian patients with advanced cirrhosis. Nutr J 2010, 9:27.
83. Rantanen T., Harris T., Leveille S.G., et al. Muscle strength and body mass index as long-term predictors of mortality in initially healthy men. JGerontol A Biol Sci Med Sci 2000, 55(3):M168-M173.
84. Durand F., Valla D. Assessment of the prognosis of cirrhosis: Child-Pugh versus MELD. JHepatol 2005, 42(Suppl 1):S100-S107.
85. Figueiredo F.A., Perez R.M., Freitas M.M., et al. Comparison of three methods of nutritional assessment in liver cirrhosis: subjective global assessment, traditional nutritional parameters, and body composition analysis. JGastroenterol 2006, 41(5):476-482.
86. Bathgate A.J., Hynd P., Sommerville D., et al. The prediction of acute cellular rejection in orthotopic liver transplantation. Liver Transpl Surg 1999, 5(6):475-479.
87. Deschenes M., Villeneuve J.P., Dagenais M., et al. Lack of relationship between preoperative measures of the severity of cirrhosis and short-term survival after liver transplantation. Liver Transpl Surg 1997, 3(5):532-537.
88. Figueiredo F., Dickson E.R., Pasha T., et al. Impact of nutritional status on outcomes after liver transplantation. Transplantation 2000, 70(9):1347-1352.
89. Le Cornu K.A., McKiernan F.J., Kapadia S.A., et al. Aprospective randomized study of preoperative nutritional supplementation in patients awaiting elective orthotopic liver transplantation. Transplantation 2000, 69(7):1364-1369.
90. Muller M.J., Lautz H.U., Plogmann B., et al. Energy expenditure and substrate oxidation in patients with cirrhosis: the impact of cause, clinical staging and nutritional state. Hepatology 1992, 15(5):782-794.
91. Shahid M., Johnson J., Nightingale P., et al. Nutritional markers in liver allograft recipients. Transplantation 2005, 79(3):359-362.
92. Tsien C.D., Shah S., Runkana A., et al. Reversal of sarcopenia predicts survival after transjugular intrahepatic portosystemic stent. Hepatology 2011, [Epub ahead of print].
93. Les I., Doval E., Flavia M., et al. Quality of life in cirrhosis is related to potentially treatable factors. Eur J Gastroenterol Hepatol 2010, 22(2):221-227.
94. Norman K., Kirchner H., Lochs H., et al. Malnutrition affects quality of life in gastroenterology patients. World J Gastroenterol 2006, 12(21):3380-3385.
95. Poon R.T., Yu W.C., Fan S.T., et al. Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther 2004, 19(7):779-788.
96. Poupon R.E., Chretien Y., Chazouilleres O., et al. Quality of life in patients with primary biliary cirrhosis. Hepatology 2004, 40(2):489-494.
97. Arguedas M.R., DeLawrence T.G., McGuire B.M. Influence of hepatic encephalopathy on health-related quality of life in patients with cirrhosis. Dig Dis Sci 2003, 48(8):1622-1626.
98. Wunsch E., Szymanik B., Post M., et al. Minimal hepatic encephalopathy does not impair health-related quality of life in patients with cirrhosis: a prospective study. Liver Int 2011, 31(7):980-984.
99. Moscucci F., Nardelli S., Pentassuglio I., et al. Previous overt hepatic encephalopathy rather than minimal hepatic encephalopathy impairs health-related quality of life in cirrhotic patients. Liver Int 2011, 31(10):1505-1510.
100. Bajaj J.S., Saeian K., Schubert C.M., et al. Minimal hepatic encephalopathy is associated with motor vehicle crashes: the reality beyond the driving test. Hepatology 2009, 50(4):1175-1183.
101. Bajaj J.S. Minimal hepatic encephalopathy matters in daily life. World J Gastroenterol 2008, 14(23):3609-3615.
102. Montomoli J., Holland-Fischer P., Bianchi G., et al. Body composition changes after transjugular intrahepatic portosystemic shunt in patients with cirrhosis. World J Gastroenterol 2010, 16(3):348-353.
103. Campillo B., Bories P.N., Pornin B., et al. Influence of liver failure, ascites, and energy expenditure on the response to oral nutrition in alcoholic liver cirrhosis. Nutrition 1997, 13(7-8):613-621.
104. Ndraha S., Hasan I., Simadibrata M. The effect of L-ornithine L-aspartate and branch chain amino acids on encephalopathy and nutritional status in liver cirrhosis with malnutrition. Acta Med Indones 2011, 43(1):18-22.
105. Dong M.H., Saab S. Complications of cirrhosis. Dis Mon 2008, 54(7):445-456.
106. Moller S., Bendtsen F., Christensen E., et al. Prognostic variables in patients with cirrhosis and oesophageal varices without prior bleeding. JHepatol 1994, 21(6):940-946.
107. Olde Damink S.W., Jalan R., Dejong C.H. Interorgan ammonia trafficking in liver disease. Metab Brain Dis 2009, 24(1):169-181.
108. Soros P., Bottcher J., Weissenborn K., et al. Malnutrition and hypermetabolism are not risk factors for the presence of hepatic encephalopathy: a cross-sectional study. JGastroenterol Hepatol 2008, 23(4):606-610.
109. Kalaitzakis E., Bjornsson E. Hepatic encephalopathy in patients with liver cirrhosis: is there a role of malnutrition?. World J Gastroenterol 2008, 14(21):3438-3439.
110. Periyalwar P., Dasarathy J., Tsien C., et al. Sarcopenia of cirrhosis results in more severe and frequent episodes of hepatic encephalopathy. Hepatology 2011, [Epub ahead of print].
111. Dasarathy S., Mullen K.D., Conjeevaram H.S., et al. Preservation of portal pressure improves growth and metabolic profile in the male portacaval-shunted rat. Dig Dis Sci 2002, 47(9):1936-1942.
112. Dasarathy S., Yang Y., Muc S., et al. Ammonia causes elevated skeletal muscle myostatin and reduced myoblast proliferation. Hepatology 2009, [Epub ahead of print].
113. McCullough A.J., Mullen K.D., Kalhan S.C. Defective nonoxidative leucine degradation and endogenous leucine flux in cirrhosis during an amino acid infusion. Hepatology 1998, 28(5):1357-1364.
114. Kung T., Springer J., Doehner W., et al. Novel treatment approaches to cachexia and sarcopenia: highlights from the 5th Cachexia Conference. Expert Opin Investig Drugs 2010, 19(4):579-585.
115. Glass D.J. Skeletal muscle hypertrophy and atrophy signaling pathways. Int J Biochem Cell Biol 2005, 37(10):1974-1984.
116. Wagers A.J., Conboy I.M. Cellular and molecular signatures of muscle regeneration: current concepts and controversies in adult myogenesis. Cell 2005, 122(5):659-667.
117. Le G.F., Rudnicki M.A. Skeletal muscle satellite cells and adult myogenesis. Curr Opin Cell Biol 2007, 19(6):628-633.
118. Garlick P.J., McNurlan M.A., Essen P., et al. Measurement of tissue protein synthesis rates invivo: a critical analysis of contrasting methods. Am J Physiol 1994, 266(3 Pt 1):E287-E297.
119. Welle S., Bhatt K., Pinkert C.A. Myofibrillar protein synthesis in myostatin-deficient mice. Am J Physiol Endocrinol Metab 2006, 290(3):E409-E415.
120. Mullen K.D., Denne S.C., McCullough A.J., et al. Leucine metabolism in stable cirrhosis. Hepatology 1986, 6(4):622-630.
121. Tessari P., Barazzoni R., Kiwanuka E., et al. Impairment of albumin and whole body postprandial protein synthesis in compensated liver cirrhosis. Am J Physiol Endocrinol Metab 2002, 282(2):E304-E311.
122. Tessari P., Inchiostro S., Barazzoni R., et al. Fasting and postprandial phenylalanine and leucine kinetics in liver cirrhosis. Am J Physiol 1994, 267(1 Pt 1):E140-E149.
123. Morrison W.L., Bouchier I.A., Gibson J.N., et al. Skeletal muscle and whole-body protein turnover in cirrhosis. Clin Sci (Lond) 1990, 78(6):613-619.
124. Tessari P., Biolo G., Inchiostro S., et al. Leucine and phenylalanine kinetics in compensated liver cirrhosis: effects of insulin. Gastroenterology 1993, 104(6):1712-1721.
125. Tugtekin I., Wachter U., Barth E., et al. Phenylalanine kinetics in healthy volunteers and liver cirrhotics: implications for the phenylalanine breath test. Am J Physiol Endocrinol Metab 2002, 283(6):E1223-E1231.
126. McCullough A.J., Tavill A.S. Disordered energy and protein metabolism in liver disease. Semin Liver Dis 1991, 11(4):265-277.
127. Guillet C., Boirie Y., Walrand S. An integrative approach to in-vivo protein synthesis measurement: from whole tissue to specific proteins. Curr Opin Clin Nutr Metab Care 2004, 7(5):531-538.
128. Holecek M., Skopec F., Sprongl L. Protein metabolism in cirrhotic rats: effect of dietary restriction. Ann Nutr Metab 1995, 39(6):346-354.
129. Lundborg H., Hamberger A. Effects of portacaval anastomosis on liver and brain protein synthesis in rats. Surgery 1977, 82(5):643-647.
130. Dunlop D.S., Kaufman H., Zanchin G., et al. Protein synthesis rates in rats with portacaval shunts. JNeurochem 1984, 43(5):1487-1489.
131. Wang Y.Y., Lin S.Y., Chuang Y.H., et al. Protein nitration is associated with increased proteolysis in skeletal muscle of bile duct ligation-induced cirrhotic rats. Metabolism 2010, 59(4):468-472.
132. Mizushima N., Komatsu M. Autophagy: renovation of cells and tissues. Cell 2011, 147(4):728-741.
133. Masiero E., Agatea L., Mammucari C., et al. Autophagy is required to maintain muscle mass. Cell Metab 2009, 10(6):507-515.
134. Kandarian S.C., Jackman R.W. Intracellular signaling during skeletal muscle atrophy. Muscle Nerve 2006, 33(2):155-165.
135. Machida S., Booth F.W. Regrowth of skeletal muscle atrophied from inactivity. Med Sci Sports Exerc 2004, 36(1):52-59.
136. Bornemann A., Maier F., Kuschel R. Satellite cells as players and targets in normal and diseased muscle. Neuropediatrics 1999, 30(4):167-175.
137. Hepple R.T. Dividing to keep muscle together: the role of satellite cells in aging skeletal muscle. Sci Aging Knowledge Environ 2006, 2006(3):e3.
138. Anthony J.C., Yoshizawa F., Anthony T.G., et al. Leucine stimulates translation initiation in skeletal muscle of postabsorptive rats via a rapamycin-sensitive pathway. JNutr 2000, 130(10):2413-2419.
139. Bodine S.C., Stitt T.N., Gonzalez M., et al. Akt/mTOR pathway is a crucial regulator of skeletal muscle hypertrophy and can prevent muscle atrophy invivo. Nat Cell Biol 2001, 3(11):1014-1019.
140. Lokireddy S., Mouly V., Butler-Browne G., et al. Myostatin promotes the wasting of human myoblast cultures through promoting ubiquitin-proteasome pathway-mediated loss of sarcomeric proteins. Am J Physiol Cell Physiol 2011, 301(6):C1316-C1324.
141. Zimmers T.A., Davies M.V., Koniaris L.G., et al. Induction of cachexia in mice by systemically administered myostatin. Science 2002, 296(5572):1486-1488.
142. Morissette M.R., Cook S.A., Buranasombati C., et al. Myostatin inhibits IGF-I-induced myotube hypertrophy through Akt. Am J Physiol Cell Physiol 2009, 297(5):C1124-C1132.
143. Trendelenburg A.U., Meyer A., Rohner D., et al. Myostatin reduces Akt/TORC1/p70S6K signaling, inhibiting myoblast differentiation and myotube size. Am J Physiol Cell Physiol 2009, 296(6):C1258-C1270.
144. Lee J.Y., Hopkinson N.S., Kemp P.R. Myostatin induces autophagy in skeletal muscle invitro. Biochem Biophys Res Commun 2011, 415(4):632-636.
145. Goldspink G. Age-related muscle loss and progressive dysfunction in mechanosensitive growth factor signaling. Ann N Y Acad Sci 2004, 1019:294-298.
146. Bush J.A., Kimball S.R., O'Connor P.M., et al. Translational control of protein synthesis in muscle and liver of growth hormone-treated pigs. Endocrinology 2003, 144(4):1273-1283.
147. Latres E., Amini A.R., Amini A.A., et al. Insulin-like growth factor-1 (IGF-1) inversely regulates atrophy-induced genes via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin (PI3K/Akt/mTOR) pathway. JBiol Chem 2005, 280(4):2737-2744.
148. Berger M.J., Doherty T.J. Sarcopenia: prevalence, mechanisms, and functional consequences. Interdiscip Top Gerontol 2010, 37:94-114.
149. Doherty T.J. Invited review: aging and sarcopenia. JAppl Physiol 2003, 95(4):1717-1727.
150. Pagadala M., Dasarathy S., Eghtesad B., et al. Posttransplant metabolic syndrome: an epidemic waiting to happen. Liver Transpl 2009, 15(12):1662-1670.
151. Guillet C., Boirie Y. Insulin resistance: a contributing factor to age-related muscle mass loss?. Diabetes Metab 2005, 31(Spec No 2). 5S20-5S26.
152. Michel R.N., Chin E.R., Chakkalakal J.V., et al. Ca2+/calmodulin-based signalling in the regulation of the muscle fibre phenotype and its therapeutic potential via modulation of utrophin A and myostatin expression. Appl Physiol Nutr Metab 2007, 32(5):921-929.
153. Sakuma K., Nakao R., Aoi W., et al. Cyclosporin A treatment upregulates Id1 and Smad3 expression and delays skeletal muscle regeneration. Acta Neuropathol 2005, 110(3):269-280.
154. Lipina C., Kendall H., McPherron A.C., et al. Mechanisms involved in the enhancement of mammalian target of rapamycin signalling and hypertrophy in skeletal muscle of myostatin-deficient mice. FEBS Lett 2010, 584(11):2403-2408.
155. Scolapio J.S., Bowen J., Stoner G., et al. Substrate oxidation in patients with cirrhosis: comparison with other nutritional markers. JPEN J Parenter Enteral Nutr 2000, 24(3):150-153.
156. Cabre E., Gonzalez-Huix F., bad-Lacruz A., et al. Effect of total enteral nutrition on the short-term outcome of severely malnourished cirrhotics. A randomized controlled trial. Gastroenterology 1990, 98(3):715-720.
157. Plauth M., Cabre E., Riggio O., et al. ESPEN guidelines on enteral nutrition: liver disease. Clin Nutr 2006, 25(2):285-294.
158. Bucuvalas J.C., Cutfield W., Horn J., et al. Resistance to the growth-promoting and metabolic effects of growth hormone in children with chronic liver disease. JPediatr 1990, 117(3):397-402.
159. Moller S., Becker U., Gronbaek M., et al. Short-term effect of recombinant human growth hormone in patients with alcoholic cirrhosis. JHepatol 1994, 21(5):710-717.
160. Donaghy A., Ross R., Wicks C., et al. Growth hormone therapy in patients with cirrhosis: a pilot study of efficacy and safety. Gastroenterology 1997, 113(5):1617-1622.
161. Wallace J.D., bbott-Johnson W.J., Crawford D.H., et al. GH treatment in adults with chronic liver disease: a randomized, double-blind, placebo-controlled, cross-over study. JClin Endocrinol Metab 2002, 87(6):2751-2759.
162. Cabral C.M., Burns D.L. Low-protein diets for hepatic encephalopathy debunked: let them eat steak. Nutr Clin Pract 2011, 26(2):155-159.
163. Gundling F., Seidl H., Pehl C., et al. How close do gastroenterologists follow specific guidelines for nutrition recommendations in liver cirrhosis? A survey of current practice. Eur J Gastroenterol Hepatol 2009, 21(7):756-761.
164. Heyman J.K., Whitfield C.J., Brock K.E., et al. Dietary protein intakes in patients with hepatic encephalopathy and cirrhosis: current practice in NSW and ACT. Med J Aust 2006, 185(10):542-543.
165. Kondrup J., Nielsen K., Juul A. Effect of long-term refeeding on protein metabolism in patients with cirrhosis of the liver. Br J Nutr 1997, 77(2):197-212.
166. Porter C., Cohen N.H. Indirect calorimetry in critically ill patients: role of the clinical dietitian in interpreting results. JAm Diet Assoc 1996, 96(1):49-57.
167. Kondrup J., Muller M.J. Energy and protein requirements of patients with chronic liver disease. JHepatol 1997, 27(1):239-247.
168. Nielsen K., Kondrup J., Martinsen L., et al. Long-term oral refeeding of patients with cirrhosis of the liver. Br J Nutr 1995, 74(4):557-567.
169. Plauth M., Roske A.E., Romaniuk P., et al. Post-feeding hyperammonaemia in patients with transjugular intrahepatic portosystemic shunt and liver cirrhosis: role of small intestinal ammonia release and route of nutrient administration. Gut 2000, 46(6):849-855.
170. Swart G.R., van den Berg J.W., van Vuure J.K., et al. Minimum protein requirements in liver cirrhosis determined by nitrogen balance measurements at three levels of protein intake. Clin Nutr 1989, 8(6):329-336.
171. Vaisman N., Katzman H., Carmiel-Haggai M., et al. Breakfast improves cognitive function in cirrhotic patients with cognitive impairment. Am J Clin Nutr 2010, 92(1):137-140.
172. Khanna S., Gopalan S. Role of branched-chain amino acids in liver disease: the evidence for and against. Curr Opin Clin Nutr Metab Care 2007, 10(3):297-303.
173. Kachaamy T., Bajaj J.S. Diet and cognition in chronic liver disease. Curr Opin Gastroenterol 2011, 27(2):174-179.
174. Anthony J.C., Anthony T.G., Kimball S.R., et al. Signaling pathways involved in translational control of protein synthesis in skeletal muscle by leucine. JNutr 2001, 131(3):856S-860S.
175. Dreyer H.C., Drummond M.J., Pennings B., et al. Leucine-enriched essential amino acid and carbohydrate ingestion following resistance exercise enhances mTOR signaling and protein synthesis in human muscle. Am J Physiol Endocrinol Metab 2008, 294(2):E392-E400.
176. Drummond M.J., Rasmussen B.B. Leucine-enriched nutrients and the regulation of mammalian target of rapamycin signalling and human skeletal muscle protein synthesis. Curr Opin Clin Nutr Metab Care 2008, 11(3):222-226.
177. Koopman R., Wagenmakers A.J., Manders R.J., et al. Combined ingestion of protein and free leucine with carbohydrate increases postexercise muscle protein synthesis invivo in male subjects. Am J Physiol Endocrinol Metab 2005, 288(4):E645-E653.
178. Katsanos C.S., Kobayashi H., Sheffield-Moore M., et al. Ahigh proportion of leucine is required for optimal stimulation of the rate of muscle protein synthesis by essential amino acids in the elderly. Am J Physiol Endocrinol Metab 2006, 291(2):E381-E387.
179. Lee S.J., Glass D.J. Treating cancer cachexia to treat cancer. Skelet Muscle 2011, 1(1):2.
180. Rode A., Fourlanos S., Nicoll A. Oral vitamin D replacement is effective in chronic liver disease. Gastroenterol Clin Biol 2010, 34(11):618-620.
181. Stamoulis I., Kouraklis G., Theocharis S. Zinc and the liver: an active interaction. Dig Dis Sci 2007, 52(7):1595-1612.
182. Yoshida Y., Higashi T., Nouso K., et al. Effects of zinc deficiency/zinc supplementation on ammonia metabolism in patients with decompensated liver cirrhosis. Acta Med Okayama 2001, 55(6):349-355.
183. Bavdekar A., Bhave S., Pandit A. Nutrition management in chronic liver disease. Indian J Pediatr 2002, 69(5):427-431.
184. Crawford B.A., Labio E.D., Strasser S.I., et al. Vitamin D replacement for cirrhosis-related bone disease. Nat Clin Pract Gastroenterol Hepatol 2006, 3(12):689-699.
185. Drummond M.J., Dreyer H.C., Pennings B., et al. Skeletal muscle protein anabolic response to resistance exercise and essential amino acids is delayed with aging. JAppl Physiol 2008, 104(5):1452-1461.
186. Wilborn C.D., Taylor L.W., Greenwood M., et al. Effects of different intensities of resistance exercise on regulators of myogenesis. JStrength Cond Res 2009, 23(8):2179-2187.
187. Koopman R., Saris W.H., Wagenmakers A.J., et al. Nutritional interventions to promote post-exercise muscle protein synthesis. Sports Med 2007, 37(10):895-906.
188. Garcia-Pagan J.C., Santos C., Barbera J.A., et al. Physical exercise increases portal pressure in patients with cirrhosis and portal hypertension. Gastroenterology 1996, 111(5):1300-1306.
189. Garcia P.S., Cabbabe A., Kambadur R., et al. Brief-reports: elevated myostatin levels in patients with liver disease: a potential contributor to skeletal muscle wasting. Anesth Analg 2010, 111(3):707-709.
190. Harrison J., McKiernan J., Neuberger J.M. Aprospective study on the effect of recipient nutritional status on outcome in liver transplantation. Transpl Int 1997, 10(5):369-374.
191. Stephenson G.R., Moretti E.W., El-Moalem H., et al. Malnutrition in liver transplant patients: preoperative subjective global assessment is predictive of outcome after liver transplantation. Transplantation 2001, 72(4):666-670.
192. Campillo B., Richardet J.P., Scherman E., et al. Evaluation of nutritional practice in hospitalized cirrhotic patients: results of a prospective study. Nutrition 2003, 19(6):515-521.